The incidence of retinopathy of prematurity (ROP) continues to rise due to the improved
survival of very low birth weight infants in developed countries. This epidemic is also fueled …

Topic To compare bevacizumab, ranibizumab, aflibercept, and laser treatment as primary
therapies for retinopathy of prematurity (ROP) in terms of retreatment rate. Clinical relevance …

Retinopathy of prematurity (ROP) is a devastating neurovascular disease of the retina in
newborn infants that can lead to vision deficits or even blindness. In this concise review we …

Purpose Intravitreal bevacizumab is increasingly used to treat severe retinopathy of
prematurity (ROP), but it enters the bloodstream, and there is concern that it may alter …

Importance Retinopathy of prematurity (ROP) is a leading cause of childhood blindness
worldwide, but treatment failure and disease recurrence are important causes of adverse …

The incidence of retinopathy of prematurity (ROP) is showing an increasing trend in the
United States. This may be because of increasing survival rates among extremely preterm …

Purpose The purpose of this study was to evaluate neurodevelopmental outcomes in 18-
month old (corrected age) preterm infants who received an intravitreal bevacizumab (IVB) …

Retinopathy of prematurity (ROP) is a leading cause of childhood blindness. However, the
pathogenesis and molecular mechanisms underlying ROP remain elusive. Herein, using the …

Purpose To evaluate neurodevelopmental outcomes after intravitreal bevacizumab (IVB)
therapy in retinopathy of prematurity (ROP) infants compared with those not exposed to IVB …

Purpose Low-dose and very low-dose intravitreal bevacizumab (IVB) have been reported to
be successful in short-term treatment of type 1 retinopathy of prematurity (ROP), down to an …